3.445USD-0.14%Mkt Cap: 357.36M USDP/E: —Last update: 2026-05-26
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601,…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap357.36M USD
Enterprise Value176.04M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-165.67M USD
Revenue/Share—
Last Price3.445 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees71
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.87
PEG—
EV/EBITDA-1.02
EV/Revenue—
P/S—
P/B2.36
EPS (TTM)-2.12
EPS (Forward)-1.25
52W Range
1.80036% of range6.420
52W High6.420 USD
52W Low1.800 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-212.17%
ROA-113.60%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-113.20M USD
CapEx (TTM)91.00K USD
FCF Margin—
FCF Yield-19.95%
Net Debt-196.61M USD
Net Debt/EBITDA1.14
Balance Sheet
Debt/Equity0.05
Current Ratio4.29
Quick Ratio4.21
Book Value/Sh1.514 USD
Cash/Share1.920 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMay 29, 2020
Analyst Consensus
Rating1.1 (Strong Buy)
Target (Mean)15.88 USD
Target Range7.000 USD – 26.00 USD
# Analysts8
Ownership
Shares Out.103.88M
Float59.99M
Insiders1.10%
Institutions85.54%
Short Interest
Short Ratio6.2d
Short % Float12.36%
Short % Out.8.00%
Shares Short8.31M
Short (prev mo.)7.64M
Technical
SMA 504.405 (-21.8%)
SMA 2004.021 (-14.3%)
Beta0.91
S&P 52W Chg28.31%
Avg Vol (30d)1.60M
Avg Vol (10d)2.00M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—